Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 1139-1145

  Guenin, Erwann ^a   Ledoux, Dominique ^a   Oudar, Olivier ^a   Lecouvey, Marc ^a   Kraemer, Michel ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Anti proliferative activity; Bisphosphonate; Structure activity; Tumor cells

Indexed keywords

1 HYDROXYMETHYLENE 1,1 BISPHOSPHONIC ACID; [(4 BROMOPHENYL)HYDROXYPHOSPHONOMETHYL]PHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BROMINE; CARBENE; CHLORINE; FLUORINE; PHENYL GROUP; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN A431; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG STRUCTURE; ESTERIFICATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; ETIDRONIC ACID; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17444398617     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Clezardin P, Fournier P, Boissier S and Peyruchaud O: In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10: 173-180, 2003.
2. Green JR: Antitumor effects of bisphosphonates. Cancer 97: 840-847, 2003.
3. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
4. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890-3894, 1997.
5. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P and Sorsa T: MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 878: 453-465, 1999.
6. Hamma-Kourbali Y, Di Benedetto M, Ledoux D, Oudar O, Leroux Y, Lecouvey M and Kraemer M: A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 310: 816-823, 2003.
7. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002.
8. van Beek ER, Lowik CW, Ebetino FH and Papapoulos SE: Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 23: 437-442, 1998.
9. Catterall JB and Cawston TE: Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther 5: 12-24, 2003.
10. Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV and Ebetino FH: Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 47: 398-402, 1995.
11. Lecouvey M, Mallard I, Bailly T, Burgada R and Leroux Y: A mild an efficient one-pot synthesis of 1-hydroxymethylene-1,1-bisphosphonic acids. Preparation of new tripod ligands. Tetrahedron Lett 42: 8475-8478, 2001.
12. Takeuchi M, Sakamoto S, Kawamuki K, Kurihara H, Nakahara H and Isomura Y: Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused azaheteroarylbisphosphonate derivatives. Chem Pharm Bull 46: 1703-1709, 1998.
13. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
14. Sebbah-Louriki M, Colombo BM, el Manouni D, Martin A, Salzmann JL, Leroux Y, Perret GY and Crepin M: A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res 22: 3925-3931, 2002.
15. Lecouvey M, Leroux Y, Kraemer M, Crepin M, El Manouni D and Lourik M: PCT Int. Appl. WO 03008425, 2003. Chem Abstr 138: 122736, 2003.
16. Schultz C: Prodrugs of biologically active phosphate esters. Bioorg Med Chem 11: 885-898, 2003.
17. Fleisch H: Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919-944, 1991.
18. Vepsalainen JJ: Bisphosphonate prodrugs. Curr Med Chem 9: 1201-1208, 2002.